Haisco Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Xiu Lian Fan

Chief Executive Officer (CEO)

CN¥1.3m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	14.3yrs
Participación del CEO	19.6%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Xiu Lian Fan (61 yo)

14.3yrs

Permanencia

CN¥1,312,900

Compensación

Ms. Xiu Lian Fan is the Managing Director and General Manager at Haisco Pharmaceutical Group Co., Ltd (Former Name: Xizang Haisco Pharmaceutical Group Co., Ltd.) and serves as its Director since August 08,...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiu Lian Fan	MD, GM & Director	14.3yrs	CN¥1.31m	19.59% CN¥ 7.5b
Wei Zhang	Deputy GM & Director	14.3yrs	CN¥780.00k	sin datos
Pangke Yan	Deputy GM & Director	3.1yrs	CN¥5.82m	0.11% CN¥ 43.7m
Jun Min Wang	Chairman	14.3yrs	CN¥1.77m	36.02% CN¥ 13.8b
Fangping Lu	Supervisor	7.8yrs	sin datos	sin datos
Bing Sheng Teng	Independent Director	7.8yrs	CN¥113.60k	sin datos
Hong Tan	Chairman of the Supervisory Board	4.5yrs	CN¥215.50k	sin datos
Jun Yan	Independent Director	7.8yrs	CN¥113.60k	sin datos
Zhengzheng Wang	Non-Employee Supervisor	5.6yrs	sin datos	0.000090% CN¥ 34.5k
Jun Le	Independent Director	4.5yrs	CN¥151.40k	sin datos
Lin Yue	Independent Director	1.3yrs	CN¥40.00k	sin datos
Chuande Cao	Independent Director	1.3yrs	CN¥40.00k	sin datos

6.7yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 002653 se considera experimentada (6.7 años de antigüedad promedio).

Haisco Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2024

Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes

Less than half of directors are independent

High number of new and inexperienced directors

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 3Q 2023)

Haisco Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Haisco Pharmaceutical Group Co., Ltd. Announces Interim Cash Dividend on A Shares for the Year 2024, Payable on 18 September 2024

Haisco Pharmaceutical Group Co., Ltd. Interim Cash Dividend for 2024

Haisco Pharmaceutical Group Co., Ltd. Proposes Interim Dividend for the First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.037 in 2Q 2023)

Haisco Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Dividend sustainability

Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2024

Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.26 in FY 2022)

Haisco Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Investor sentiment improves as stock rises 17%

Haisco Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.031 in 3Q 2022)

Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes

Second quarter 2023 earnings released: EPS: CN¥0.037 (vs CN¥0.052 in 2Q 2022)

New minor risk - Share price stability

Full year 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.031 (vs CN¥0.043 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.031 in 2Q 2021)

Haisco Pharmaceutical Group Co., Ltd. Announces 2021 Final Profit Cash Distribution Plan to Be Implemented (A Shares), Payable on 05 July 2022

Haisco Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend for 2021

Haisco Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 35 million in funding from Haisco Holdings Pte. Ltd., Haisight Holdings PTE.LTD.

Haisco Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.32 (vs CN¥0.59 in FY 2020)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.043 loss per share (vs CN¥0.17 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.031 (vs CN¥0.09 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.59 (vs CN¥0.46 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥22.12

Starton Therapeutics Inc. and Haisco Pharmaceutical Group Co., Ltd. Enter into Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China

Haisco Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥17.25

New 90-day low: CN¥19.06

New 90-day low: CN¥21.43

Third quarter earnings released

Wang Junmin and Fan Xiulian intends to acquire 63.41% stake in Chengdu Sailanuo Medical Technology Co., Ltd. from Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) for approximately CNY 320 million.

New 90-day low: CN¥21.91

Haisco Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 820.7371 million in funding

New 90-day low - CN¥23.19

First half earnings released

Haisco Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 19, 2020

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad